BioWorld MedTech

April 2, 2012

Corindus meets primary endpoints for PRECISE trial

Corindus Vascular Robotics (Natick, Massachusetts) reported it has met the primary endpoints for its PRECISE trial and results indicate the Corpath 200 System could be considered as a safer alternative to manual PCI. Read More

Trust thy lender, but pay heed to thine term sheet

Report from Europe: Abbott gains CE mark for PLEX-ID System

Washington roundup: NHS wants multi-disciplinary team for aortic valve implants

Deals roundup: HeartWare to acquire WorldHeart for $8M

MDD's Fun Facts

Financings roundup: HIT Application Solutions secures $2.75M for Notifi

HIT roundup: Lovelace selects ZeOmega Jive for integrated care

Agreements/contracts: Accuray in collaboration pact with U. of Heidelberg

Restructuring roundup: HR to lay off 3% of workforce to deal with med-device tax

Product Briefs

St. Jude pulls Brio DBS off European market

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for July 13, 2026.

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

NRF2 activators reported in Vailima Peninsula patent

BioWorld Science

Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...